CN103622940B - The application of gossypol acetate in pharmacy - Google Patents
The application of gossypol acetate in pharmacy Download PDFInfo
- Publication number
- CN103622940B CN103622940B CN201310547165.6A CN201310547165A CN103622940B CN 103622940 B CN103622940 B CN 103622940B CN 201310547165 A CN201310547165 A CN 201310547165A CN 103622940 B CN103622940 B CN 103622940B
- Authority
- CN
- China
- Prior art keywords
- gossypol acetate
- mecp2
- thunder
- medicine
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of novelty teabag of gossypol acetate in pharmaceutical field, be specifically related to the application of gossypol acetate in preparation prevention, alleviation and/or treatment thunder syndrome medicine, belong to pharmaceutical field.Thunder syndrome is a kind of agnogenic Reye syndrome in children's's period, and research finds the loss of MeCP2 gene or has direct cause effect relation between sudden change and thunder syndrome, and the loss of this gene can cause mice to occur thunder Cotard.The present invention's experiment shows, by by gossypol acetate to rat administration, obviously can increase the content of MeCP2 gene in rat brain, it can thus be appreciated that, gossypol acetate is used for prevent, alleviate and treat and is suddenlyd change in the thunder syndrome that causes by MeCP2, obviously can increase the content of brain in patients MeCP2 gene, promote the growth of patient neurons, thus its neural function is restored, increase the probability that patient cures.Therefore, the application of gossypol acetate in the anti-thunder syndrome medicine of preparation, makes this medicine can be used for prevention, alleviates and/or treatment thunder syndrome.
Description
Technical field
The present invention relates to the application of gossypol acetate at pharmaceutical field, the particularly application of gossypol acetate in the anti-thunder syndrome medicine of preparation.
Background technology
Thunder syndrome is a kind of neurodevelopment autism spectrum disorder (autismspectrumdisorder) of serious X-linkage, be the MeCP2(methylCpG – bindingprotein2 generally acknowledged both at home and abroad, Methylated CpG binding proteins 2) single-gene causes a disease disease.Research finds the loss of MeCP2 gene or has direct cause effect relation between sudden change and thunder syndrome, for thunder syndrome provides potential treatment target.Find the research of thunder syndrome mouse model, the recovery of its MeCP2 function can make the neurological symptoms result of adult mice reverse, thunder syndrome patient is had cure possibility.
Gossypol acetate is Malvaceae plant cotton, tree cotton or Gossypium hirsutum L. mature seed, a kind of polyhydric phenols with extensive pharmacological action of extracting in root bark, have the effects such as antifertility, anti-inflammatory, antiviral, its chemical structural formula is as follows:
Refining gossypol acetate is used as man's birth control medicine with the dosage of 20mg/ days by prior art, significantly reduces the survival rate of sperm; Clinical research finds that the gynaecopathia such as tumor, endometriosis of gossypol acetate to men and women's reproductive system also has obvious inhibitory action.
Realizing in process of the present invention, inventor finds that prior art at least exists following problem:
The research of prior art Dichlorodiphenyl Acetate gossypol purposes mainly concentrates on the gynaecopathia aspect such as tumor, endometriosis for the treatment of men and women reproductive system, not yet finds that it treats the application in the thunder syndrome medicine of MeCP2 sudden change in preparation.
Summary of the invention
Being confined to the problem of oncotherapy in order to solve prior art gossypol acetate range of application, the object of the present invention is to provide the novelty teabag of gossypol acetate in pharmacy, the concrete technical scheme realizing this object is as follows:
Embodiments provide gossypol acetate to prevent in preparation, alleviate and/or treat the application in the medicine of thunder syndrome.
The solution of technical scheme of the present invention is based on following experimental result: the embodiment of the present invention passes through pharmacological experiment, to Oral Administration in Rats gossypol acetate, then respectively western-blot(western blotting is carried out to blank group and gossypol acetate group) and SABC mensuration, and obtain western-blot figure and the ImmunohistochemistryResults Results schematic diagram of blank group and gossypol acetate group respectively, as seen from the figure: gossypol acetate group is compared with blank group, and the content of the MeCP2 in rat whole brain improves significantly; The content of the MeCP2 in rat layer is also significantly improved.Visible gossypol acetate can significantly improve the content of MeCP2 in rat brain, namely gossypol acetate can significantly improve the content of MeCP2 gene in rat brain, promote the growth of patient neurons, thus its neural function is restored, increase the probability that patient cures.It can thus be appreciated that gossypol acetate may be used for the thunder syndrome medicine preparing anti-MeCP2 sudden change.
Particularly, the medicine of described prevention, alleviation and/or treatment thunder syndrome is the gossypol acetate of prevention or treatment effective dose, and wherein gossypol acetate is separately as the active component in medicine.
Particularly, the pharmaceutical pack of described prevention, alleviation and/or treatment thunder syndrome containing prevention or treatment effective dose gossypol acetate, with other medicine classes of gossypol acetate compatibility and optional pharmaceutically acceptable carrier and/or adjuvant, alternatively, gossypol acetate wherein also can be prepared into the derivant of the clinical acceptable medicine relevant with its pharmacology.
Particularly, the dosage form of the medicine of described prevention, alleviation and/or treatment thunder syndrome is selected from solution, suspension agent, Emulsion, pill, capsule, powder agent, Controlled release formulation and extended release preparation.
Particularly, the administering mode of the medicine of described prevention, alleviation and/or treatment thunder syndrome is selected from oral administration, nose administration, parenteral or rectally, canalis spinalis administration, intravenous injection, intramuscular injection, subcutaneous injection.
The beneficial effect that the technical scheme that the embodiment of the present invention provides is brought is:
Embodiments provide the application that gossypol acetate is new in pharmacy, by gossypol acetate is suddenlyd change in the medicine of the thunder syndrome caused for the preparation of prevention, alleviation and treatment by MeCP2, make this medicine obviously can increase the content of MeCP2 gene in brain in patients, promote the growth of patient neurons, thus its neural function is restored, increase the probability that patient cures.
Accompanying drawing explanation
In order to be illustrated more clearly in the technical scheme in the embodiment of the present invention, below the accompanying drawing used required in describing embodiment is briefly described, apparently, accompanying drawing in the following describes is only some embodiments of the present invention, for those of ordinary skill in the art, under the prerequisite not paying creative work, other accompanying drawing can also be obtained according to these accompanying drawings.
Fig. 1 a and Fig. 1 b is in the rat whole brain that provides of the embodiment of the present invention one respectively, gossypol acetate group and blank western-blot(Western blotting organize) qualitative figure with quantitatively scheme;
Fig. 2 a and Fig. 2 b is in the rat cerebral cortex that provides of the embodiment of the present invention one respectively, gossypol acetate group and blank western-blot(Western blotting organize) qualitative figure with quantitatively scheme;
Fig. 3 is the MeCP2 dyeing ImmunohistochemistryResults Results schematic diagram of the gossypol acetate group cortex that the embodiment of the present invention two provides;
Fig. 4 is the MeCP2 dyeing ImmunohistochemistryResults Results schematic diagram of the blank group cortex that the embodiment of the present invention two provides;
Fig. 5 is the ImmunohistochemistryResults Results schematic diagram of the blank group that the embodiment of the present invention two provides.
Wherein, the blank group of A;
B gossypol acetate group;
CMeCP2；
D actin;
EMeCP2/ β actin relative expression quantity (with blank group for benchmark).
Detailed description of the invention
For making the object, technical solutions and advantages of the present invention clearly, below in conjunction with accompanying drawing, embodiment of the present invention is described further in detail.
Embodiment of the present invention instrument equipment and raw material as follows:
Instrument and equipment:
MQX200 microplate reader (BioTek, the U.S.);
JY92-II DN ultrasonic cell disruptor (NingBo XinZhi Biology Science Co., Ltd);
EPS-300 electrophresis apparatus (Shanghai Tian Neng Science and Technology Ltd.);
VE-180 Vertial electrophorestic tank (Shanghai Tian Neng Science and Technology Ltd.);
VE-186 electrophoretic blotting groove (Shanghai Tian Neng Science and Technology Ltd.);
ChemiDoxXRS gel imaging system (BIO-RAD, the U.S.);
K30 dry-type thermostat (Hangzhou Ao Sheng Instrument Ltd.);
PE20 laboratory pH meter (prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit instrument (Shanghai) limited public company);
AL104-IC electronic balance (prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit instrument (Shanghai) limited public company);
BX53 system microscope (OLYMPUS(Olympus), Japan);
BT100-2J peristaltic pump (Baoding LanGe constant flow pump Co., Ltd);
RM2245 paraffin slicing machine (Leica, Germany).
Raw material:
Gossypol acetate: purchased from middle cotton purple light biotechnology company, outward appearance: yellow or buff powder, the efficient Liquid Detection of CASNo:12542-36-8, specification: 98%();
Ripabuffer(buffer): use distilled water to dissolve 0.6055gTris(Tris), 0.8766gNaCl, 1mlNP-40(Nonidet P40), 0.5g NaTDC and 0.1gSDS(sodium lauryl sulphate), and be settled to 100ml with distilled water;
100mMPMSF(Phenylmethanesulfonyl fluoride, mM is mmol/L): be dissolved in by 0.174gPMSF in 10ml isopropyl alcohol, subpackage ,-20 DEG C of storages, add in Ripabuffer with the ratio of PMSF:Ripabuffer=1:100 during use;
100mMDTT(dithiothreitol, DTT): 0.154gDTT is dissolved in 10ml distilled water, subpackage ,-20 DEG C of storages, and the used time adds in Ripabuffer with the ratio of DTT:Ripabuffer=1:100;
Electrophoretic buffer: use distilled water to dissolve 3.03gTris, 18.77g glycine and 1.0gSDS, and be settled to 1000ml with distilled water;
30%Acr/Bis(29:1) solution (acrylamide/methylene diacrylamide): use distilled water to dissolve 29g acrylamide and 1g methylene diacrylamide, and be settled to 100ml with distilled water, keep in Dark Place at 4 DEG C;
Separation gel buffer: use distilled water to dissolve 18.165gTris, adjust pH to 8.8, and be settled to 100ml with distilled water;
Concentrated glue buffer: use distilled water to dissolve 12.11gTris, adjust pH to 6.8, and be settled to 100ml with distilled water;
10%SDS: use distilled water to dissolve 10gSDS, and be settled to 100ml with distilled water;
The Ammonium persulfate. of 10%: by 0.1g Ammonium persulfate., adds in 0.1ml distilled water and dissolves, subpackage, preserves 1 week for 4 DEG C, preserves January for-20 DEG C;
Electricity turns buffer: use distilled water to dissolve 3.03gTirs, 14.41g glycine, 200ml methanol, and be settled to 1000ml with distilled water;
TBS buffer: use distilled water to dissolve 6.055gTris, 8.766gNaCl, adjust pH to 7.5, and be settled to 1000ml with distilled water;
The Tween-20(tween 20 of 0.04% is added) in TBS-T:TBS buffer;
Confining liquid: containing the TBS-T solution of 5% defatted milk powder;
Ponceaux dye liquor: use distilled water to dissolve 0.2g Ponceau S, 3g sulfosalicylic acid and 3g trichloroacetic acid, and be settled to 100ml with distilled water;
PBS buffer (PhosphateBufferSolution: phosphate buffer): use distilled water to dissolve 8g sodium chloride (NaCl), 0.2g potassium chloride (KCl), 1.44g sodium hydrogen phosphate (Na2HPO4), 0.24g potassium dihydrogen phosphate (KH2PO4), adjust pH to 7.4, and be settled to 1000ml with distilled water;
ABC immunohistochemical kit: purchased from Wuhan doctor's moral company limited, model: SA1022, specification: 1/2KIT;
DAB colour reagent box: purchased from Le Bo biotech firm, model: AR1022.
Embodiment one: western-blot(western blotting) measure the impact of gossypol acetate on Mecp2 content in rat brain
The embodiment of the present invention takes western-blot(Western blotting) method, determine the change of the content of Mecp2 in rat brain, concrete steps are as follows:
Get 56 8 weeks large male SPF level (SpeceficpathogenFree, no-special pathogen) wistar(rat), be divided into 2 groups at random: blank group (giving edible oil and distilled water), gossypol acetate group (give gossypol acetate 50mg/kg and distilled water, now 50mg/kg refers to the single dose giving every kg rat is 50mg).By above-mentioned rat sub-cage rearing, ad lib is drunk water, and keeps indoor temperature 25 ± 1 DEG C, relative humidity 55 ± 5%, 12h illumination/12h dark cycle illumination.Administering mode is oral administration, and except blank group, Dichlorodiphenyl Acetate gossypol group carries out modeling, successive administration two weeks in every other day medicine feed mode once.Above-mentioned 2 groups of rats were put to death after sub-cage rearing respectively through two weeks, drew materials.
To draw materials process:
Above-mentioned rat is after two weeks sub-cage rearings, and the chloral hydrate (W/V) with 10% is anaesthetized, and the ratio that anesthesia amount gives 0.3-0.4ml injection volume in every 100g rat is determined.The above-mentioned each group of rat broken end of having anaesthetized is got brain, and isolate complete brain, then brain is separated into cortical tissue, hippocampal tissue and appurtenance, uses dry ice freezing immediately, and be put in-80 DEG C of refrigerators respectively by blank group and gossypol acetate group and carry out preservation and can complete and draw materials.
Sample preparation:
(1) cut the freezing rat cortical tissue of appropriate above-mentioned rat and brain whole brain tissue (cortical tissue, hippocampal tissue and appendicular mixture) on ice respectively, weigh;
(2) in above-mentioned weighed cerebral cortex sample and the full brain sample of brain, add the Ripabuffer lysate (containing DTT, PMSF) of 10 times of volumes respectively, with ultrasonic (the work 2s of ultrasonic cell disintegration instrument, interval 3s, power 125W, omnidistance 3min) prepare tissue homogenate;
(3) homogenate hatches 30min on ice;
(4) homogenate is with 12000rpm centrifugal 10min at 4 DEG C;
(5) abandon precipitation after centrifugal and get supernatant, be cerebral cortex sample to be measured and the full brain sample of brain;
(6) BCA (acid of bicinchoninincacid dihomocinchonine) method measures cerebral cortex sample to be measured and brain full brain sample total protein concentration;
(7) utilize SDS sample-loading buffer, above-mentioned cerebral cortex sample and brain full brain sample protein concentration are adjusted to isoconcentration;
(8) above-mentioned cerebral cortex sample and brain full brain sample dry-type thermostat 98 DEG C heating 3min are carried out degeneration, be cooled to room temperature for subsequent use.
Denaturing polyacrylamide gel electrophoresis:
(1) by the SDS-PAGE(sodiumdodecylsulfatepolyacrylamidegelelectropho resis of 10%: polyacrylamide gel electrophoresis) separation gel is fully mixed evenly, poured in preprepared glue plate, water seal, room temperature is placed 30-60min and is solidified (separation gel and water intersection can see a straight line clearly) to separation gel;
(2) after gelling to be separated admittedly, water is outwelled, blots with absorbent paper, plug loading comb, the SDS-PAGE of 5% is concentrated glue and fill with in loading comb, get rid of bubble, leave standstill the extremely concentrated gelling of 15-30min solid.
(3) respectively ready for sample preparation steps cerebral cortex sample and the full brain sample of brain are added in gel pore gently;
(4) electrophresis apparatus is arranged to voltage stabilizing state, is adjusted to 70V ~ 40min, enter until above-mentioned each sample and be adjusted to 140V ~ 90min after separation gel and carry out electrophoresis;
(5) when bromophenol blue indicatrix is by plastic emitting, stop electrophoresis, prepare transferring film.
Transferring film:
(1) by plastic stent, foam-rubber cushion, filter paper, PVDF(PolyvinylideneFluoride: polyvinylidene fluoride) film etc. turn in liquid at electricity balance 5min(PVDF film and need soak into through 100% methanol);
(2) after electrophoresis terminates, plastic stent keeps flat (black-film under), places foam-rubber cushion, 2 thickness filter paper, gel, transfer film, 2 thickness filter paper, foam-rubber cushion successively, and drives each interlayer bubble away, clip support, put into electrophoresis transferring groove;
(3) electrophresis apparatus is arranged to current stabilization state, is adjusted to 200mA ~ 90min, in ice bath, carry out electricity turn;
(4) after electricity turns end, take out film and carry out labelling, with the dyeing of Ponceaux dye liquor, methanol decolouring, to a visible protein band, is observed transfer effect, and film is suitably cut out one-tenth transfer film for subsequent use.
Antigen antibody reaction:
(1) transfer film is put into confining liquid, close at 4 DEG C and spend the night;
(2) transfer film closed is put into hybridization bag, add the primary antibodie (anti-MeCP2 antibody) of appropriate confining liquid dilution by the size of film, eliminate bubble sealing, 4 DEG C of overnight incubation.
(3) transfer film is taken out, with TBS-T solution washing three times, each 10min;
(4) film is put into hybridization bag, adds HRP(horseradish peroxidase) corresponding two anti-(rabbit anti-mouse igg two that HRP combines resists) of labelling, eliminate bubble sealing, shaken at room temperature hatches 2h.
(5) transfer film is taken out, with TBS-T solution washing three times, each 10min.
Chromogenic reaction:
(1) A liquid and the B liquid (A liquid is luminol (Luminol) and special luminescence enhancer, and B liquid is stabilizer of hydrogen peroxide) of ECL electrogenerated chemiluminescence reagent is got, even by 1:1 volume mixture;
(2) transfer membrane of hatching is put into the plate of suitable size, get ECL mixed liquor and be added on transfer film, film is contacted with uniform liquid, lucifuge reaction 5min;
(3) transfer film is put into gel imaging system to carry out exposing and carry out qualitative analysis to it, and with ImageJ software, semi-quantitative analysis is carried out to slice result, namely obtain the western-blot figure of rat cerebral cortex and the full brain of brain.
The embodiment of the present invention has been carried out testing to blank group and gossypol acetate group respectively by said method and has been obtained the western-blot figure of blank group and gossypol acetate group respectively, from Fig. 1 a and Fig. 1 b: gossypol acetate group is compared with blank group, and the content of the MeCP2 in rat whole brain improves significantly; From Fig. 2 a and Fig. 2 b: gossypol acetate group is compared with blank group, and the content of the MeCP2 in rat layer is also significantly improved; Visible, gossypol acetate can significantly improve the content of MeCP2 in rat brain.Embodiment of the present invention experiment shows, by by gossypol acetate to rat administration, obviously can increase the content of MeCP2 gene in rat brain, it can thus be appreciated that, gossypol acetate is used for prevent, alleviate and treat and is suddenlyd change in the thunder syndrome that causes by MeCP2, obviously can increase the content of brain in patients MeCP2 gene, promote the growth of patient neurons, thus its neural function is restored, increase the probability that patient cures.Therefore, the application of gossypol acetate in the anti-thunder syndrome medicine of preparation, makes this medicine can be used for prevention, alleviates and/or treatment thunder syndrome.
Embodiment two: immunohistochemistry assays measures gossypol acetate to the impact of Mecp2 content in rat brain
Get 56 8 weeks large male SPF level (SpeceficpathogenFree, no-special pathogen) wistar(rat), be divided into 2 groups at random: blank group (giving edible oil and distilled water), gossypol acetate group (gives gossypol acetate 50mg/kg and distilled water, now 50mg/kg refers to the single dose giving every kg rat is 50mg), by above-mentioned rat sub-cage rearing, ad lib is drunk water, and keeps indoor temperature 25 ± 1 DEG C, relative humidity 55 ± 5%, 12h illumination/12h dark cycle illumination.Administering mode is oral administration, and except blank group, Dichlorodiphenyl Acetate gossypol group carries out modeling, successive administration two weeks in every other day medicine feed mode once.Above-mentioned 2 groups of rats were put to death after sub-cage rearing respectively through two weeks, drew materials.
To draw materials process:
First carry out 4% paraformaldehyde perfusion to the rat of above-mentioned grouping, and after administration 2h, anaesthetize with 10% chloral hydrate (W/V), the ratio that anesthesia amount gives 0.3-0.4ml injection volume in every 100g rat is determined.The above-mentioned each group of rat of having anaesthetized is cut off skin, thoracic cavity successively, fully exposes heart, cut off left side apex, insert from left ventricle to pour into syringe needle towards aorta direction, to aorta internal fixtion, hemostasis clamp closes.First with the quick perfusion of PBS buffer, cutting at left auricle allows blood and perfusate flow out flatly, treat that effluent starts to bleach, change with 4% paraformaldehyde liquid, continue perfusion about 10min, take out rat whole brain, be placed in 4% paraformaldehyde, spend the night, within second day, to cut with blade and repair Hippocampus place crown, continue fixing 24h.Cerebral tissue takes out by sucrose fixative, distilled water flushing 3 times, the section of 5 μm of transverse section is made of thermostat slicer freezer, section is mounted on micro slide, then dehydration of alcohol at different levels following each time period: 50% ethanol (2min) → 70% ethanol (2min) → 80% ethanol (2min) → 95% ethanol (2min) → 100% ethanol (2min), preserve stand-by at then the section after dehydration being placed in-20 DEG C.Transparent with dimethylbenzene again, piece of tissue puts into fritting state cake wax, fully infiltrates, is embedded down by tangent plane.Slice thickness 5 μm, be affixed on and scribble APES(3-aminopropyl-3-(ethoxymethyl) silane) on the slide of anticreep tablet, put on hot plate and make its extended flat with a small amount of water, slide is continued to be placed on hot plate and bake to completely dry, be then placed in 370C oven cooking cycle 6h and can complete and draw materials and obtain print.
Dewaxing and aquation:
(1) dimethylbenzene I 30min, dimethylbenzene II 30min.
(2) 100% ethanol I, II, 95% ethanol I, II, 80% ethanol respectively carries slotting 10 times.
(3) distilled water washes twice
Antigen retrieval:
Adopt Microwave method method,
(1) the PBS buffer of 0.01M is developed a film, 5min × 3 time;
The H of (2) 3%
2o
2lucifuge incubated at room 1h;
(3) the PBS buffer of 0.01M is developed a film, 5min × 3 time;
(4) citrate buffer of 0.01M, high fiery 2min in microwave oven, low fiery 5min, dries in the air cool;
(5) the PBS buffer of 0.01M is developed a film, 5min × 3 time;
(6) antigen retrieval buffers (citrate buffer) lucifuge incubated at room 10min;
(7) the PBS buffer of 0.01M is developed a film, 5min.
Antibody incubation:
(1) 5%BSA (BovineSerumAlbumin: bovine serum albumin) room temperature closes 1h;
(2) drip primary antibodie (anti-Mecp2 antibody), 4 DEG C of 16h, incubated at room 30min, hatch 30min for 37 DEG C;
(3) the PBS buffer of 0.01M is developed a film, 5min × 3 time;
(4) dripped for two anti-(rabbit anti-mouse igg two that HRP combines resists, ABC immunohistochemical kit), hatch 1h for 37 DEG C;
(5) 0.01MPBS buffer is developed a film, 5min × 3 time;
Development dyeing (SABC(SABC) method):
(1) SABC(oxide enzyme is dripped), hatch 30min for 37 DEG C;
(2) 0.01MPBS buffer is developed a film, 5min × 3 time;
(3) DAB colour developing 5-10min(DAB colour reagent box), distilled water color development stopping is reacted, and this process controls developing time under the microscope;
The each 3min of (4) 95% ethanol I, II, each 5min of 100% ethanol I, II, III;
(5) each 10min of dimethylbenzene I, II, III;
(6) resinene mounting.
The embodiment of the present invention has carried out SABC mensuration by the MeCP2 of the said method rat sample cortex of Dichlorodiphenyl Acetate gossypol group, blank group and blank group respectively.(gossypol acetate group adds MeCP2 primary antibodie to the MeCP2 colored graph of wherein gossypol acetate group cortex, granule brown in figure represents MeCP2 albumen) as shown in Figure 3, (blank group adds MeCP2 primary antibodie to the MeCP2 colored graph of blank group cortex, granule brown in figure represents MeCP2 albumen) as shown in Figure 4, the ImmunohistochemistryResults Results schematic diagram (blank group does not add MeCP2 primary antibodie) of blank group is as shown in Figure 5.
From Fig. 3 and Fig. 4, the MeCP2 colored graph of the gossypol acetate group cortex after gossypol acetate administration group adds MeCP2 primary antibodie is compared with adding the MeCP2 colored graph of the blank group cortex after MeCP2 primary antibodie, wherein the quantity of MeCP2 albumen (i.e. brown particle) is significantly increased, in addition, as shown in Figure 5, do not add existence MeCP2 albumen substantially not detected in the blank group ImmunohistochemistryResults Results schematic diagram of MeCP2 primary antibodie, the visible content utilizing gossypol acetate administration to significantly increase MeCP2 in rat brain, namely gossypol acetate can significantly improve the content of MeCP2 gene in rat brain.
Embodiment of the present invention experiment shows, by by gossypol acetate to rat administration, obviously can increase the content of MeCP2 gene in rat brain, it can thus be appreciated that, gossypol acetate is used for prevent, alleviate and treat and is suddenlyd change in the thunder syndrome that causes by MeCP2, obviously can increase the content of brain in patients MeCP2 gene, promote the growth of patient neurons, thus its neural function is restored, increase the probability that patient cures.Therefore, the application of gossypol acetate in the anti-thunder syndrome medicine of preparation, makes this medicine can be used for prevention, alleviates and/or treatment thunder syndrome.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (4)
1. gossypol acetate prevents in preparation, alleviates and/or treat the application in the thunder syndrome medicine of MeCP2 sudden change.
2. gossypol acetate according to claim 1 prevents in preparation, alleviates and/or treat the application in the thunder syndrome medicine of MeCP2 sudden change, it is characterized in that, described medicine is prevention or the gossypol acetate for the treatment of effective dose.
3. gossypol acetate according to claim 1 and 2 prevents in preparation, alleviates and/or treat the application in the thunder syndrome medicine of MeCP2 sudden change, it is characterized in that, the dosage form of described medicine is selected from tablet, solution, suspension agent, Emulsion, pill, capsule, powder agent, Controlled release formulation and extended release preparation.
4. gossypol acetate according to claim 1 and 2 prevents in preparation, alleviates and/or treat the application in the thunder syndrome medicine of MeCP2 sudden change, it is characterized in that, the administering mode of described medicine is selected from oral administration, nose administration, canalis spinalis administration, intravenous injection, intramuscular injection, subcutaneous injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310547165.6A CN103622940B (en) | 2013-11-06 | 2013-11-06 | The application of gossypol acetate in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310547165.6A CN103622940B (en) | 2013-11-06 | 2013-11-06 | The application of gossypol acetate in pharmacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103622940A CN103622940A (en) | 2014-03-12 |
| CN103622940B true CN103622940B (en) | 2016-02-24 |
Family
ID=50204629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310547165.6A Expired - Fee Related CN103622940B (en) | 2013-11-06 | 2013-11-06 | The application of gossypol acetate in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103622940B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109908119A (en) * | 2019-04-25 | 2019-06-21 | 中国科学院化学研究所 | The agent of LRPPRC negative regulation and purposes |
| WO2022166933A1 (en) * | 2021-02-05 | 2022-08-11 | 上海科技大学 | Anti-coronavirus application of compound |
| CN114377053A (en) * | 2022-01-18 | 2022-04-22 | 云南贝泰妮生物科技集团股份有限公司 | Cooling gel dressing and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327201A (en) * | 2007-06-20 | 2008-12-24 | 上海市计划生育科学研究所 | Gossypol or liquid preparation of analogue thereof and preparation method and use thereof |
| CN101896068A (en) * | 2007-10-19 | 2010-11-24 | 伯恩哈姆医学研究协会 | The naphthyl inhibitor of anti-apoptotic proteins |
| CN103260612A (en) * | 2010-10-25 | 2013-08-21 | 艾克斯-马赛大学 | Treatment of mecp2-ssociated disorders |
-
2013
- 2013-11-06 CN CN201310547165.6A patent/CN103622940B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327201A (en) * | 2007-06-20 | 2008-12-24 | 上海市计划生育科学研究所 | Gossypol or liquid preparation of analogue thereof and preparation method and use thereof |
| CN101896068A (en) * | 2007-10-19 | 2010-11-24 | 伯恩哈姆医学研究协会 | The naphthyl inhibitor of anti-apoptotic proteins |
| CN103260612A (en) * | 2010-10-25 | 2013-08-21 | 艾克斯-马赛大学 | Treatment of mecp2-ssociated disorders |
Non-Patent Citations (1)
| Title |
|---|
| 棉酚以及衍生物的化学和应用研究概况;吴国沛等;《有机化学》;19851230(第3期);193-201页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103622940A (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamiel et al. | Glutamine enhances heat shock protein 70 expression via increased hexosamine biosynthetic pathway activity | |
| Reinecke | The kidney as a source of glucose in the eviscerated rat | |
| CN103622940B (en) | The application of gossypol acetate in pharmacy | |
| Katoh et al. | Porcine sperm capacitation involves tyrosine phosphorylation and activation of aldose reductase | |
| CN109232718B (en) | Synthetic peptide sp2 and application thereof | |
| Rajendram et al. | Glutamine in clinical nutrition | |
| Cai et al. | Therapeutic hypothermia combined with hydrogen sulfide treatment attenuated early blood–brain barrier disruption and brain edema induced by cardiac arrest and resuscitation in rat model | |
| Hori et al. | Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow | |
| WO2019091013A1 (en) | Use of no donor compound for preparing drug for inhibiting invasion and metastasis ability of tumor cell rich in mercapto molecules | |
| CN108864037B (en) | TRPML1 specific agonist, application of TRPML1 specific agonist as autophagy inhibitor and preparation of tumor treatment drug, and pharmaceutical composition | |
| Wu et al. | Erythropoietin suppresses D-galactose-induced aging of rats via the PI3K/Akt/Nrf2-ARE pathway | |
| CN115177608A (en) | Application of long-chain acyl carnitine compound in preparation of medicine for preventing and/or treating liver cancer | |
| CN104223056B (en) | Purposes of the colla carapacis et plastri testudinis in the drug of preparation treatment tumour | |
| CN109316482B (en) | Application of clozapine in preparation of tumor treatment drug and application of clozapine serving as autophagy inhibitor and pharmaceutical composition | |
| CN105194653B (en) | Zinc finger protein 30 7（ZNF307）Application in myocardial hypertrophy is treated | |
| CN104922700A (en) | Experimental method for applying Sirt1-Nrf2 novel oxidation resisting pathway in oxidative damage treatment | |
| CN109276598A (en) | Fruit of glossy privet glucosides enriched substance and application thereof | |
| CN117122669B (en) | Application of recombinant human growth hormone in treating central diabetes insipidus | |
| CN105997843A (en) | Preparing technology for ferrous lactate syrup | |
| BR102019014892A2 (en) | COMPOSITION OF HYPERIMUNE EQUINE PLASMA MICROCAPSULAS, PROCESS FOR OBTAINING THE SAME, COMPOSITION OF VETERINARY HEMO PRODUCT CONTAINING HYPERIMUNE EQUINE PLASMA MICROCAPSULAS AND USES THEREOF | |
| CN105708828A (en) | Application of caffeic acid in preparation of drugs for treating hepatic microcirculation disturbance and hepatic injury | |
| Valitova et al. | Anemia of chronic diseases: a verdict or a protective reaction of the body? | |
| CN105311045A (en) | Application of ginsenoside Rg1 to preparation of medicines for prevention and/or treatment of myocardial ischemia | |
| KR101655048B1 (en) | Method for the assessment of mother's milk quality which exposed to trans fat | |
| CN117503740A (en) | BACH1 inhibitor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160224 Termination date: 20191106 |